ImmunoTherapeutics

OSE Immunotherapeutics is a clinical-stage biotechnology company based in France that specializes in developing first-in-class immunotherapies for cancer and autoimmune diseases. The company's lead asset, Tedopi, is a neoepitope-based cancer vaccine currently in a pivotal Phase 3 trial for non-small cell lung cancer patients with secondary resistance to immune checkpoint inhibitors. Another key program, lusvertikimab (OSE-127), is an anti-IL-7 receptor antibody that recently demonstrated positive Phase 2 results in ulcerative colitis. OSE has established high-value strategic partnerships with major pharmaceutical companies, including a $713 million deal with AbbVie for OSE-230 and a multi-program collaboration with Boehringer Ingelheim worth over €1.1 billion. The company leverages three proprietary drug discovery platforms to target myeloid cells, T-cell activation, and immune resolution to address significant unmet medical needs.